[HTML][HTML] Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in …
RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific reports, 2017 - nature.com
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
[HTML][HTML] Combination of ruthenium (II)-arene complex [Ru (η6-p-cymene) Cl2 (pta)](RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in …
RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific …, 2017 - ncbi.nlm.nih.gov
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
Combination of ruthenium (II)-arene complex [Ru (η-p-cymene) Cl (pta)](RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …
RH Berndsen, A Weiss, UK Abdul… - Scientific …, 2017 - researchinformation.amsterdamumc …
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …
RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific …, 2017 - europepmc.org
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
Combination of ruthenium (II)-arene complex [Ru (η6-p-cymene) Cl2 (pta)](RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …
RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific …, 2017 - hero.epa.gov
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
[PDF][PDF] Archive ouverte UNIGE
RH Berndsen, A Weiss, UK Abdul, TJ Wong, P Meraldi… - access.archive-ouverte.unige.ch
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …
RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific …, 2017 - search.ebscohost.com
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …
RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific …, 2017 - ui.adsabs.harvard.edu
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
[PDF][PDF] Robert H. Berndsen1, Andrea Weiss2, U. Kulsoom Abdul1, Tse J. Wong1, Patrick Meraldi3
AW Griffioen, PJ Dyson, P Nowak-Sliwinska - researchgate.net
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
Combination of ruthenium (II)-arene complex [Ru (η6-p-cymene) Cl2 (pta)](RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …
RH Berndsen, A Weiss, UK Abdul, TJ Wong, P Meraldi… - Scientific reports, 2017 - sonar.ch
English Ruthenium-based compounds show strong potential as anti-cancer drugs and are
being investigated as alternatives to other well-established metal-based chemotherapeutics …
being investigated as alternatives to other well-established metal-based chemotherapeutics …